Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders

Medical Hypotheses

Volumn 65, Issue 2, 2005, Pages 392-394

  Yamagishi, S ^a   Nakamura, K ^a   Takeuchi, M ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM ANTAGONIST; DIHYDROPYRIDINE; NIFEDIPINE; REACTIVE OXYGEN METABOLITE; SCHIFF BASE;

AMADORI REARRANGEMENT; ARTICLE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; HYPOTHESIS; INFLAMMATION; MELANOMA; METASTASIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

CALCIUM; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NIFEDIPINE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 19744364874     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.12.016     Document Type: Article

References (12)

1. M. Brownlee Advanced protein glycosylation in diabetes and aging Ann Rev Med 46 1995 223 234
2. S.K. Grandhee, and V.M. Monnier Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors J Biol Chem 266 1991 11649 11653
3. S. Yamagishi, M. Takeuchi, Y. Inagaki, K. Nakamura, and T. Imaizumi Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy Int J Clin Pharmacol Res 23 2003 129 134
4. H. Vlassara, R. Bucala, and L. Striker Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging Lab Invest 70 1994 138 151
5. A. Bierhaus, M.A. Hofmann, R. Ziegler, and P.P. Nawroth AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept Cardiovasc Res 37 1998 586 600
6. A.M. Schmidt, and D. Stern Atherosclerosis and diabetes: the RAGE connection Curr Atheroscler Rep 2 2000 430 436
7. R. Abe, T. Shimizu, H. Sugawara, H. Watanabe, H. Nakamura, and H. Choei Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions J Invest Dermatol 122 2004 461 476
8. S. Yamagishi, Y. Inagaki, S. Amano, T. Okamoto, M. Takeuchi, and Z. Makita Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties Biochem Biophys Res Commun 296 2002 877 882
9. T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, K. Koga, and R. Abe Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin FASEB J 16 2002 1928 1930
10. S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, and H. Yamamoto Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells Diabetologia 41 1998 1435 1441
11. Y. Yamamoto, I. Kato, T. Doi, H. Tonekura, S. Ohashi, and M. Takeuchi Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice J Clin Invest 108 2001 261 268
12. S. Yamagishi, and M. Takeuchi Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation Drugs Exp Clin Res 30 2004 169 175